Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?

Biotech giant Gilead Sciences, Inc. (GILD) , a leader in HIV drugs, is having a tough run as recent pipeline setbacks disappointed investors and acquisition-related charges adversely impacted the bottom line. The stock has been under pressure owing to these challenges.While the company’s leading HIV franchise maintains momentum and its efforts to build an oncology franchise to diversify its portfolio are encouraging, the failure of late-stage studies evaluating oncology drug Trodelvy (sacituzumab govitecan) ...